Anabolic processes

Anabolic processes represent the constructive phase of metabolism, wherein cells assemble complex macromolecules—such as proteins, polynucleotides, and lipids—from simpler molecular precursors [10, 14]. These biosynthetic pathways are endergonic, requiring a consistent input of energy typically provided by adenosine triphosphate (ATP) generated through catabolic reactions [12, 15]. Anabolic activity is fundamental to essential physiological functions, including cell proliferation, tissue regeneration, bone mineralization, and the storage of energy in the form of glycogen or triglycerides [12, 13]. While the term 'Anabolic processes' describes a vital biological state, it is not considered a discrete therapeutic target in a pharmacological sense; rather, it defines a broad category of pathways regulated by numerous distinct enzymes and receptors [11, 14]. Pharmacological interventions aimed at modulating anabolism typically target specific mediators like the Androgen Receptor (AR) to treat muscle-wasting conditions such as cachexia, or the mechanistic Target of Rapamycin (mTOR) to suppress the pathologically heightened anabolic state characteristic of malignant tumors [1, 11]. Consequently, while many drugs are described as 'anabolic agents,' they exert their effects through specific molecular components within these larger metabolic networks [2, 5].

Other names

AnabolismBiosynthesisConstructive metabolismAnabolic metabolism

Drugs modulate anabolic processes by acting as agonists or inhibitors of specific regulatory proteins, such as the androgen receptor, the growth hormone receptor, or the mechanistic target of rapamycin (mTOR), which collectively orchestrate the synthesis of cellular biomass and energy storage.